DnB Asset Management
RYTM icon

DnB Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

DnB Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$974K Buy
11,195
+32
+0.3% +$3.11K ﹤0.01% 649
2025
Q4 		$1.19M Buy
11,163
+5,635
+102% +$598K ﹤0.01% 628
2025
Q3 		$558K Buy
+5,528
New +$513K ﹤0.01% 668

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DnB Asset Management's RYTM Position: Q1 2026 in Review

DnB Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 0.29% in Q1 2026, buying an estimated $3.11K and bringing the position to 11,195 shares worth $974K. The position accounts for ﹤0.01% of the portfolio, ranked #649.

DnB Asset Management first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • DnB Asset Management held 11,195 shares of Rhythm Pharmaceuticals worth $974K as of Q1 2026.
  • DnB Asset Management bought 32 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.11K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q1 2026, its #649 holding.
  • DnB Asset Management first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • DnB Asset Management's Rhythm Pharmaceuticals position peaked at $1.19M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.